120 related articles for article (PubMed ID: 33180422)
21. [Clinical significance of serum cytokeratin 19 fragment in the prediction of chemotherapy efficacy and prognosis in patients with advanced non-small cell lung cancer].
Xu C; Liu J; Xing L; Liu S
Zhongguo Fei Ai Za Zhi; 2010 Oct; 13(10):954-61. PubMed ID: 20959068
[TBL] [Abstract][Full Text] [Related]
22. Serum Sialyl Lewis x and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer.
Mizuguchi S; Nishiyama N; Iwata T; Nishida T; Izumi N; Tsukioka T; Inoue K; Uenishi T; Wakasa K; Suehiro S
Lung Cancer; 2007 Dec; 58(3):369-75. PubMed ID: 17697728
[TBL] [Abstract][Full Text] [Related]
23. Circulating CD15
Tian X; Wang T; Zheng Q; Tao Y; Dai L; Shen H
Int J Clin Pract; 2021 Aug; 75(8):e14317. PubMed ID: 33960078
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic Value and Clinical Significance of Combined Detection of Serum Markers CYFRA21-1, SCC Ag, NSE, CEA and ProGRP in Non-Small Cell Lung Carcinoma.
Li Q; Sang S
Clin Lab; 2020 Nov; 66(11):. PubMed ID: 33180443
[TBL] [Abstract][Full Text] [Related]
25. Translational value of IDH1 and DNA methylation biomarkers in diagnosing lung cancers: a novel diagnostic panel of stage and histology-specificity.
Zang R; Wang X; Jin R; Lei Y; Huang J; Liu C; Zheng S; Zhou F; Wu Q; Sun N; Gao S; He J
J Transl Med; 2019 Dec; 17(1):430. PubMed ID: 31888670
[TBL] [Abstract][Full Text] [Related]
26. Identification of isocitrate dehydrogenase 1 as a potential diagnostic and prognostic biomarker for non-small cell lung cancer by proteomic analysis.
Tan F; Jiang Y; Sun N; Chen Z; Lv Y; Shao K; Li N; Qiu B; Gao Y; Li B; Tan X; Zhou F; Wang Z; Ding D; Wang J; Sun J; Hang J; Shi S; Feng X; He F; He J
Mol Cell Proteomics; 2012 Feb; 11(2):M111.008821. PubMed ID: 22064513
[TBL] [Abstract][Full Text] [Related]
27. CYFRA21-1 tests in the diagnosis of non-small cell lung cancer: A meta-analysis.
Fu L; Wang R; Yin L; Shang X; Zhang R; Zhang P
Int J Biol Markers; 2019 Sep; 34(3):251-261. PubMed ID: 31436122
[TBL] [Abstract][Full Text] [Related]
28. [Usefulness of CYFRA21-1 as a tumor marker of non-small-cell lung cancer].
Tan Y; Zhang P; Zheng C
Zhonghua Zhong Liu Za Zhi; 1999 Jul; 21(4):287-9. PubMed ID: 11776818
[TBL] [Abstract][Full Text] [Related]
29. Clinical utility of haptoglobin in combination with CEA, NSE and CYFRA21-1 for diagnosis of lung cancer.
Wang B; He YJ; Tian YX; Yang RN; Zhu YR; Qiu H
Asian Pac J Cancer Prev; 2014; 15(22):9611-4. PubMed ID: 25520076
[TBL] [Abstract][Full Text] [Related]
30. [Detection and diagnostic value of serum carcinoembryonic antigen and cytokeratin 19 fragment in lung cancer patients].
Hang ZQ; Zheng MF; Huang JH
Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):847-9. PubMed ID: 22335951
[TBL] [Abstract][Full Text] [Related]
31. Serum thrombospondin-2 is a candidate diagnosis biomarker for early non-small-cell lung cancer.
Jiang YM; Yu DL; Hou GX; Jiang JL; Zhou Q; Xu XF
Biosci Rep; 2019 Jul; 39(7):. PubMed ID: 31296790
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic significance of S100A2 and S100A6 levels in sera of patients with non-small cell lung cancer.
Wang T; Liang Y; Thakur A; Zhang S; Yang T; Chen T; Gao L; Chen M; Ren H
Tumour Biol; 2016 Feb; 37(2):2299-304. PubMed ID: 26361956
[TBL] [Abstract][Full Text] [Related]
33. Application of serum microRNA-9-5p, 21-5p, and 223-3p combined with tumor markers in the diagnosis of non-small-cell lung cancer in Yunnan in southwestern China.
Yang Y; Chen K; Zhou Y; Hu Z; Chen S; Huang Y
Onco Targets Ther; 2018; 11():587-597. PubMed ID: 29430184
[TBL] [Abstract][Full Text] [Related]
34. [Clinical value of combined detection of serum tumor markers in lung cancer diagnosis].
Chen F; Li WM; Wang DM; Gao SS; Bao Y; Chen WB; Liu D
Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Sep; 39(5):832-5. PubMed ID: 19024326
[TBL] [Abstract][Full Text] [Related]
35. Assessment of Seven Clinical Tumor Markers in Diagnosis of Non-Small-Cell Lung Cancer.
Chen ZQ; Huang LS; Zhu B
Dis Markers; 2018; 2018():9845123. PubMed ID: 30647803
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic and prognostic value of serum thioredoxin and DJ-1 in non-small cell lung carcinoma patients.
Fan J; Yu H; Lv Y; Yin L
Tumour Biol; 2016 Feb; 37(2):1949-58. PubMed ID: 26334622
[TBL] [Abstract][Full Text] [Related]
37. Detection of circulating exosomal miR-17-5p serves as a novel non-invasive diagnostic marker for non-small cell lung cancer patients.
Zhang Y; Zhang Y; Yin Y; Li S
Pathol Res Pract; 2019 Aug; 215(8):152466. PubMed ID: 31146974
[TBL] [Abstract][Full Text] [Related]
38. Serum THBS2 is a potential biomarker for the diagnosis of non-small cell lung cancer.
Xiong L; Zhu C; Lu Y; Chen M; Li M
J Cancer Res Clin Oncol; 2023 Nov; 149(17):15671-15677. PubMed ID: 37658862
[TBL] [Abstract][Full Text] [Related]
39. [Plasma mannan?binding lectin and MBL?associated serine protease 2 in patients with hepatocellular carcinoma].
Li J; Zhu LY; Zuo DM; Zhang LY; Lu X; Chen ZL; Zhou J
Nan Fang Yi Ke Da Xue Xue Bao; 2017 Dec; 37(12):1667-1672. PubMed ID: 29292263
[TBL] [Abstract][Full Text] [Related]
40. A re-evaluation of squamous cell carcinoma antigen (SCC) as a serum marker for non-small cell lung cancer.
Kagohashi K; Satoh H; Ishikawa H; Ohtsuka M; Sekizawa K
Med Oncol; 2008; 25(2):187-9. PubMed ID: 17968682
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
